decitabine
Selected indexed studies
- Decitabine/Cedazuridine: First Approval. (Drugs, 2020) [PMID:32860582]
- Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. (Lancet Haematol, 2024) [PMID:38135371]
- Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. (Blood, 2021) [PMID:33876188]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Decitabine/Cedazuridine: First Approval. (2020) pubmed
- Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. (2024) pubmed
- Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. (2021) pubmed
- Decitabine. (2014) pubmed
- Decitabine. (2003) pubmed
- Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. (2024) pubmed
- Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. (2023) pubmed
- Decitabine. (2010) pubmed
- Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. (2021) pubmed
- Decitabine--bedside to bench. (2007) pubmed